Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>Claire Wainwright, Michael Boyle, Carla Colombo et al.|New England Journal of Medicine|2015Cited by 1.6k
The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosisEnrico Costa, Marco Cipolli, Silvia Girotti et al.|Orphanet Journal of Rare Diseases|2022Cited by 51
Traits, trends and hits of orphan drug designations in cystic fibrosisEnrico Costa, Hubert G. M. Leufkens, Jennifer L. Taylor‐Cousar et al.|Journal of Cystic Fibrosis|2023Cited by 6
Ataluren improves hematopoietic and pancreatic disorders in Shwachman-Diamond syndrome patients: a compassionate program case-seriesValentino Bezzerri, Marco Cipolli|Nature Communications|2025Cited by 1